Last10K.com

Acasti Pharma Inc. (ACST) SEC Filing 6-K Foreign Issuer report for the period ending Thursday, February 13, 2020

SEC Filings

Acasti Pharma Inc.

CIK: 1444192 Ticker: ACST

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

 

For the month of: February 2020 Commission File Number: 001-35776

 

 

ACASTI PHARMA INC.

(Name of Registrant)

 

545 Promende du Centropolis
Suite 100
Laval, Québec
Canada H7T 0A3
(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  ☒            Form 40-F  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes  ☐             No  ☒

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

 

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

ACASTI PHARMA INC.
Date: February 14, 2020 By: /s/ Jan D’Alvise                                  
   

Name: Jan D’Alvise

Title: Chief Executive Officer

 

 

 

 

 
 

 

EXHIBIT INDEX

 

   
Exhibit Description of Exhibit
   
99.1 Management’s Discussion and Analysis of the Financial Situation and Operating Results - For the Three and Nine-Month Periods Ended December 31, 2019 and 2018
   
99.2 Financial Statements for the Three-Month and Nine-Month Periods Ended December 31, 2019 and 2018
   
99.3 Form 52-109F2 – Certification of Interim Filings - Full Certificate (CEO)
   
99.4 Form 52-109F2 – Certification of Interim Filings - Full Certificate (VP, Finance)

 

 

 

 

 

 

 

 

View differences made from one to another to evaluate Acasti Pharma Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Acasti Pharma Inc..

Continue

Assess how Acasti Pharma Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Acasti Pharma Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Material Contracts, Statements, Certifications & more

Acasti Pharma Inc. provided additional information to their SEC Filing as exhibits

Ticker: ACST
CIK: 1444192
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001171843-20-000981
Submitted to the SEC: Fri Feb 14 2020 8:00:15 AM EST
Accepted by the SEC: Fri Feb 14 2020
Period: Thursday, February 13, 2020
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/acst/0001171843-20-000981.htm